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RISK FACTORS AND OUTCOMES OF SURGICAL SITE
INFECTIONS IN DIABETICS UNDERGOING CARDIAC
SURGERY
Kumar N1, Dao T2, Gentry L2, Garey KW1
1University of Houston, College Of Pharmacy, Houston,TX, USA; 2St.
Luke’s Episcopal Hospital, Houston,TX, USA
OBJECTIVE: Previous studies on risk factors for postoperative
surgical site infections (SSI) have identiﬁed presence of diabetes
as a major risk factor for development of SSI following cardiac
surgery. However, why certain diabetics are more likely to
develop SSI than others is unknown. The purpose of this study
was to identify risk factors and outcomes of SSI in diabetics
undergoing cardiac surgery. METHOD: Nested, case-control
study. Patients with diabetes undergoing coronary artery bypass
or valve replacement surgery at St. Luke’s Episcopal Hospital,
Houston, Texas, who experienced a post-operative SSI (n = 71)
in 2002–2004 were compared to randomly selected, uninfected
controls (n = 103) whom underwent similar surgery during the
same time period. Clinical data was collected to determine risk
factors and outcomes using univariate statistics and multivariate
logistic regression. RESULTS: History of cardiac disorders (con-
gestive heart failure, stroke, angina, or myocardial infarction)
(OR = 1.589; 95% CI = 1.132–2.230; p = 0.0075) and obesity
(OR = 2.849; 95% CI = 1.241–6.542; p = 0.0136) were identi-
ﬁed as signiﬁcant independent risk factors for SSI in diabetics
undergoing cardiac surgery. Cases were hospitalized an average
eight-days longer than uninfected controls (p = 0.0006) and
experienced twice as many complications requiring reoperation
(10.6% vs. 21%; p = 0.057). CONCLUSION: Cardiac history
and obesity were identiﬁed as signiﬁcant risk factors for SSI in
our diabetic patient population. SSI signiﬁcantly increased hos-
pital length of stay in our diabetic population.
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9301 COST-EFFECTIVENESS OF LONG-TERM THERAPY WITH
CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY
INTERVENTION: A SWEDISH ANALYSIS OF THE CREDO-TRIAL
Ringborg A1, Lindgren P1, Jönsson B2
1Stockholm Health Economics, Stockholm, Sweden; 2Stockholm
School of Economics, Stockholm, Sweden
OBJECTIVES: The CREDO trial demonstrated the clinical efﬁ-
cacy of 12-month therapy with clopidogrel, with a 27% RRR (p
= 0.02) combined risk of death, MI, or urgent target revascu-
larization in patients undergoing percutaneous coronary inter-
vention (PCI) and being treated with ASA. The purpose of 
this study was to evaluate the long-term cost-effectiveness of 
12-month versus 28-day therapy with clopidogrel in Sweden.
METHODS: A Markov model was developed, enabling model-
ling over the longer term. A hypothetical cohort of patients in a
post-PCI state was assumed to have certain risks of suffering one
of the endpoints of the CREDO trial: stroke, MI or death. First-
year risks were taken from the observed rates of the CREDO
trial while risks for following years were estimated based on epi-
demiological data, provided by the Centre for Epidemiology at
the Swedish National Board of Health and Welfare. Cost data
was collected from published sources. The perspective was that
of society. Effectiveness was measured as the number of life-years
gained from long-term treatment with clopidogrel. Cost-
effectiveness acceptability curves were created using bootstrap-
ping to estimate parameter uncertainty and Monte Carlo simu-
lation to estimate the effect of this uncertainty in the model.
RESULTS: The model predicted a mean survival of 12.35 years
in the 12-month arm compared to 12.28 in the 28-day arm, an
incremental gain of 0.065 life-years. The increase in survival
came at a predicted incremental cost of 171€, resulting in an
incremental cost-effectiveness ratio (ICER) of 2637€. If only
direct costs were considered, the ICER was 7588€. If costs due
to increased survival were included, the ICER was 14,681€.
Results were insensitive to variations in costs and discount rates.
CONCLUSIONS: The predicted cost-effectiveness ratio of long-
term treatment with clopidogrel in patients undergoing PCI is
well below the threshold values currently considered cost-
effective.
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ASSOCIATION BETWEEN LONG-TERM USE OF NSAIDS/
COX-2 INHIBITORS AND CARDIOVASCULAR RISK–A
RETROSPECTIVE ANALYSIS USING THE VETERAN AFFAIRS
(VA) DATABASE
Motsko SP1, Rascati KL1, Barner JC1, Busti AJ2, Lawson KA1,
Wilson JP1
1University of Texas, Austin,TX, USA; 2Texas Tech University, Dallas,
TX, USA
The search for less gastrointestinal toxic nonsteroidal anti-
inﬂammatory drugs (NSAIDs) led to the introduction of the
selective cyclooxygenase-2 (COX-2) inhibitors. However, with
this introduction into the market, there have been concerns
regarding their safety, particularly cardiovascular safety. OBJEC-
TIVE: The purpose of this study was to assess the cardiovascu-
lar risk (events included: myocardial infarction, stroke, and
myocardial infarction-related deaths) associated with long-term
use (after 180 days of exposure) of nonselective NSAIDs and
COX-2 inhibitors. METHODS: A retrospective analysis of the
Veterans Integrated Service Network 17 Veteran’s Affairs (VA)
database was conducted. Medicare data and Department of
Health mortality data were incorporated to capture events occur-
ring outside the VA health care network. Patients 35 years of age
and older receiving celecoxib, rofecoxib, ibuprofen, etodolac,
and naproxen from January 1, 1999 through December 31,
2001, were included. Multivariate Cox proportional hazard
models were used to analyze the relationship between cardio-
vascular risk and NSAID/COX-2 inhibitor use while adjusting
for various demographic and co-morbidity factors. RESULTS:
We identiﬁed 6814 long-term exposure periods and 42 cardio-
vascular events over the study period. Compared to long-term
ibuprofen use, long-term use of celecoxib was associated with a
3.64 fold (95% CI 1.36–9.70; p = 0.01) increase in cardiovas-
cular risk. Long-term use of rofecoxib was associated with a 6.64
fold (95% CI 2.17–20.28; p = < 0.01) increased risk when com-
pared to long-term users of ibuprofen. Long-term exposure to
naproxen and etodolac was not associated with a cardionegative
or cardioprotective effect when compared to long-term ibupro-
fen users. CONCLUSIONS: The ﬁndings of this observational
study along with recent clinical trial results suggest that 
long-term exposure to COX-2 inhibitors is associated with 
an increased cardiovascular risk. In addition, the study results
do not show that naproxen or etodolac provide a cardioprotec-
tive or cardionegative effect.
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COST OF URINARY INCONTINENCE IN GERMANY: RESULTS
FROM PROSPECTIVE URINARY RESEARCH (PURE)
Finnern HW1, Hampel C2, Blanke M3, Graf v.d. Schulenburg JM3
1Lilly Deutschland GmbH, Bad Homburg, Germany; 2Johannes
Gutenberg University, Mainz, Germany; 3University of Hannover,
Hannover, Germany
OBJECTIVE: Estimate direct medical costs of Urinary Inconti-
nence (UI), namely Stress Urinary Incontinence (SUI), Mixed
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Urinary Incontinence (MUI) and Urge Urinary Incontinence
(UUI) in Germany over 12 months. METHODS: PURE is an
ongoing six-month, pan-European, prospective observational
study to determine direct treatment costs for women with UI.
Analysis includes 2175 German patients (mean age 65.1 years)
with SUI (n = 487), MUI (n = 1457) or UUI (n = 231) symptoms.
Participating investigators are ofﬁce based primary care physi-
cians (n = 110), urologists (n = 185), gynaecologists (n = 100)
and other (n = 4). Resource use data for cost estimation was col-
lected retrospectively including medication, conservative treat-
ment, diagnostic and surgical procedures, incontinence products
and visits to health care providers for 12 months preceding base-
line. Unit costs for 2004 from the perspective of statutory health
insurance (SHI) were used. RESULTS: Average total annual costs
for women with UI ranged from 413.0€ for SUI, 438.0€ for UUI
to 585.2€ for MUI. Costs were primarily attributable to pad
costs for SUI (223.5€), MUI (300.3€) and UUI (235.0€). A total
of 52.4% of pad costs were incurred by SHI, with remaining
costs being paid out-of-pocket. Average drug costs were 47.4€
for SUI, 86.1€ for MUI and 107.2€ for UUI. Patients receiving
UI surgery had average surgical costs of 3326.9€. On average,
26.9% of patients with SUI, 44.0% with MUI and 52.8% with
UUI were treated with UI medication, while 10.3% of patients
with SUI, 16.8% with MUI and 17.5% with UUI were ever
treated with surgery. Pad use ranged from 85%, 87.2% to 89.2%
in SUI, MUI and UUI patients, respectively. CONCLUSION:
Patients with MUI were found to incur the highest costs com-
pared to patients with other UI subtypes. Patients with SUI were
treated with UI medication not indicated for use in SUI. Inci-
dence of previous UI surgery was considerable in this treatment
seeking population.
CS6
TREATMENT OF INSTITUTIONALIZED PATIENTS WITH
ALZHEIMER’S DISEASE WITH QUETIAPINE: A COST-
EFFECTIVENESS EVALUATION
Getsios D1, O’Brien J2, Caro JJ2, Pesa J3
1Caro Research Institute, Hammonds Plains, NS, Canada; 2Caro
Research, Concord, MA, USA; 3AstraZeneca LP, Wilmington, DE, USA
OBJECTIVE: Over 75% of individuals with Alzheimer’s disease
(AD) residing in nursing homes have behavioral and psycholog-
ical signs of dementia (BPSD). Quetiapine is an atypical antipsy-
chotic that has demonstrated effectiveness in the treatment of
BPSD. This analysis examines the health economic implications
of treating patients with AD and BPSD with quetiapine at a dose
of 200mg per day. METHODS: A discrete event simulation was
developed to compare treatment of institutionalized AD patients
in the US with quetiapine relative to no pharmacological treat-
ment. The model follows individuals over one year, tracking
changes in BPSD and the resulting inﬂuence on costs. Effective-
ness and treatment persistence estimates are based on a ran-
domized, double-blind trial comparing quetiapine to placebo,
while BPSD related nursing home costs are derived from the
Minnesota Case Mix Research Database and published infor-
mation. Costs in the simulation, which are reported in 2004 US
dollars, include nursing home per diems, physician visits, psy-
chiatric and behavioral services, and treatment with quetiapine.
The primary effectiveness outcome is time without clinically sig-
niﬁcant BPSD. RESULTS: Untreated patients incur costs averag-
ing $49,350 per year, clinically signiﬁcant BPSD apparent 87%
of the time. Treatment with quetiapine costs $1142 per year, but
this is entirely offset in savings from other areas, resulting in net
savings of $44 per year. At the same time, patients spend seven
fewer weeks with clinically signiﬁcant BPSD. In repeated simu-
lations, quetiapine dominated no treatment in almost 60% of
replications. In 94% of replications, quetiapine was either dom-
inant or led to incremental costs per BPSD year avoided of under
$5000. Sensitivity analyses showed that variations in BPSD-
speciﬁc nursing home costs had the strongest impact on out-
comes. CONCLUSIONS: These analyses indicate that quetiap-
ine in patients with AD and BPSD is cost-effective and may even
lead to overall health care system savings.
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OVERCOMING SAMPLE-SELECTION CHALLENGES IN
ECONOMIC COMPARISONS OF DRUG AND NON-DRUG
THERAPY: THE CASE OF OVERACTIVE BLADDER
Ollendorf DA1, Jumadilova Z2,Varadharajan S1, Girase P1
1PharMetrics, Inc, Watertown, MA, USA; 2Pﬁzer, Inc, New York, NY,
USA
OBJECTIVE: To assess whether comparable populations can be
created to assess the economic impact of different treatment
strategies for overactive bladder (OAB). METHODS: Data 
were obtained from the PharMetrics Patient-Centric Database 
on patients diagnosed with OAB between January, 2001 and
December, 2002. Patients were stratiﬁed into those receiving a
pharmacological therapy for OAB (ie, long-acting tolterodine,
immediate- or extended-release oxybutynin) versus medical 
management alone. Patients were matched 1 :1 by the estimated
propensity score for OAB pharmacotherapy. A logistic regression
model included selected demographic and clinical characteristics.
A ﬁtted probability of receipt of OAB medication was generated
for all patients, and matching was performed based on a differ-
ence of ± 0.01 in this probability. Differences in patient charac-
teristics as well as outcomes and costs during follow-up were
assessed using descriptive statistics (chi-squares for proportions,
Wilcoxon rank-sum tests for continuous variables). RESULTS:
A total of 29,992 matched pairs were identiﬁed. Patients aver-
aged 50 years of age, and 75% were women. After matching,
differences in all patient characteristics were nonsigniﬁcant, with
the exception of physician specialty. Both groups had a pre-index
Charlson Comorbidity Index of 0.70. The incidence of urinary
tract infection was higher in the group receiving medical man-
agement alone (27.4% vs. 20.2%, p < 0.0001). Mean (± SD)
OAB-related costs were also signiﬁcantly higher in the medical
management group ($454 ± $2559 vs. $253 ± $1985, p <
0.0001). Pharmacy costs were higher in the drug-treated group,
but total costs (OAB-related and unrelated) were numerically
similar ($8666 ± $22,757 vs. $8674 ± $20,496), suggesting that
high pharmacological costs of treatment are offset by reduction
in other OAB- and infection-related costs. CONCLUSIONS:
Creation of comparable cohorts is feasible, even when treatment
interventions differ substantially. Furthermore, OAB pharma-
cotherapy appears to be cost-neutral in the management of the
condition, and may impart selected clinical beneﬁts.
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ECONOMIC EVALUATION OF ONDANSETRON VERSUS
DIMENHYDRINATE FOR PREVENTION OF POSTOPERATIVE
VOMITING IN CHILDREN
Piwko C1, Lasry A1,Alanezi K1, Coyte PC1, Ungar WJ2
1University of Toronto,Toronto, ON, Canada; 2The Hospital for Sick
Children,Toronto, ON, Canada
OBJECTIVE: Postoperative vomiting (POV) is a distressing com-
plication and its incidence ranges from 34%–90% in children
undergoing strabismus surgery when antiemetics are not ad-
ministered prophylactically. This study compares the economic
beneﬁt of ondansetron versus dimenhydrinate as antiemetics
administered prophylactically in children undergoing strabismus
surgery. METHODS: This study, conducted at Toronto’s Hospi-
